92% RFS at 2 Years: PD-1 Immunotherapy for MMRd / MSI-H Tumors at AACR 2025 AACR 2 Mins Read A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
AMTAGVI [lifileucel] FDA Approved Game-Changer in Melanoma Treatment? Here’s What You Need to Know. Melanoma Skin Cancer Treatment 5 Mins Read What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in…
